Aarti Pharmalabs achieves SBTi approval of GHG emission reduction targets
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
Sensory Boxes include items such as drawing boards and fidget balls to support management of anxiety and improve shopping experience
PRX-PLUS has a unique product feature with its deep-impacting formula
GE HealthCare’s Revolution Vibe CT enables more facilities to elevate patient care by offering advanced cardiac imaging technology
The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market
Nipaguard SCE Vita delivers comprehensive antimicrobial protection for personal care formulations
Subscribe To Our Newsletter & Stay Updated